Geneva Capital Management LLC Buys 420,078 Shares of Vericel Co. (NASDAQ:VCEL)

Geneva Capital Management LLC increased its stake in Vericel Co. (NASDAQ:VCEL - Free Report) by 61.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,104,386 shares of the biotechnology company's stock after purchasing an additional 420,078 shares during the period. Geneva Capital Management LLC owned 2.25% of Vericel worth $46,660,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in VCEL. Victory Capital Management Inc. lifted its stake in Vericel by 2.0% in the third quarter. Victory Capital Management Inc. now owns 623,627 shares of the biotechnology company's stock valued at $26,348,000 after buying an additional 12,481 shares during the last quarter. Baker Avenue Asset Management LP lifted its position in Vericel by 24.0% in the 3rd quarter. Baker Avenue Asset Management LP now owns 44,187 shares of the biotechnology company's stock valued at $1,867,000 after purchasing an additional 8,542 shares during the last quarter. TimesSquare Capital Management LLC lifted its position in Vericel by 54.8% in the 3rd quarter. TimesSquare Capital Management LLC now owns 590,145 shares of the biotechnology company's stock valued at $24,934,000 after purchasing an additional 209,009 shares during the last quarter. Atria Investments Inc boosted its stake in Vericel by 21.6% during the 3rd quarter. Atria Investments Inc now owns 7,768 shares of the biotechnology company's stock valued at $328,000 after purchasing an additional 1,378 shares during the period. Finally, Summit Global Investments grew its position in Vericel by 105.4% in the 3rd quarter. Summit Global Investments now owns 20,831 shares of the biotechnology company's stock worth $880,000 after purchasing an additional 10,691 shares during the last quarter.

Insider Buying and Selling at Vericel

In other news, Director Steven C. Gilman sold 5,833 shares of Vericel stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $40.35, for a total transaction of $235,361.55. Following the transaction, the director now owns 11,000 shares in the company, valued at approximately $443,850. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Vericel news, Director Steven C. Gilman sold 5,833 shares of the company's stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $40.35, for a total value of $235,361.55. Following the transaction, the director now owns 11,000 shares in the company, valued at approximately $443,850. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Dominick Colangelo sold 17,500 shares of the stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total value of $724,150.00. Following the sale, the chief executive officer now owns 220,937 shares of the company's stock, valued at approximately $9,142,373.06. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 29,166 shares of company stock valued at $1,200,764 in the last three months. 5.20% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on VCEL shares. Stephens boosted their price objective on Vericel from $56.00 to $58.00 and gave the stock an "overweight" rating in a research report on Friday, August 2nd. Truist Financial increased their price target on Vericel from $56.00 to $57.00 and gave the stock a "buy" rating in a research note on Tuesday, July 16th. Canaccord Genuity Group initiated coverage on shares of Vericel in a report on Friday, August 9th. They issued a "buy" rating and a $57.00 price objective for the company. StockNews.com raised shares of Vericel from a "sell" rating to a "hold" rating in a research note on Friday, November 8th. Finally, Canaccord Genuity Group initiated coverage on shares of Vericel in a research note on Friday, August 9th. They issued a "buy" rating and a $57.00 price target for the company. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $57.71.

Vericel Stock Down 1.2 %

Shares of NASDAQ VCEL traded down $0.68 during mid-day trading on Wednesday, hitting $55.21. 244,174 shares of the company traded hands, compared to its average volume of 430,349. Vericel Co. has a 1 year low of $32.31 and a 1 year high of $57.81. The stock has a market capitalization of $2.73 billion, a price-to-earnings ratio of 917.15 and a beta of 1.66. The business has a 50 day moving average of $44.51 and a two-hundred day moving average of $46.56.

Vericel (NASDAQ:VCEL - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.05) by $0.03. Vericel had a net margin of 1.56% and a return on equity of 1.48%. The company had revenue of $57.91 million during the quarter, compared to analyst estimates of $55.32 million. As a group, research analysts anticipate that Vericel Co. will post 0.13 EPS for the current year.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.